Clinical trial
Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal…
NCT00113217 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00113217 |
|---|---|
| Title | Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma |
| Official title | A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of Recombinant Humanized Monoclonal Anti-VEGF Antibody rhuMab VEGF (Bevacizumab) for Renal Cell Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma, Kidney Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab |
| Enrollment | 52 |
| Start date | Feb 1, 2005 |
| Primary completion | Aug 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Jun 7, 2005 |
| Last update posted | Sep 23, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: